| Application | Recommended Dilution |
|---|---|
| ELISA | 1:5000-1:50000 |
Thymic stromal lymphopoietin (TSLP) serves as a critical cytokine at the interface of epithelial barrier function and immune activation. Produced primarily by epithelial cells, keratinocytes, and stromal cells, TSLP drives dendritic cell maturation and promotes Th2-skewed immune responses, positioning it as a central mediator in allergic inflammation, asthma pathogenesis, and atopic dermatitis. Its emerging roles in tumor microenvironment modulation and autoimmune conditions have further expanded research interest in this versatile cytokine.
This recombinant monoclonal antibody (clone 9F9) offers researchers the reproducibility essential for longitudinal studies and multi-site collaborations. Because the antibody sequence is defined and production occurs in controlled recombinant systems, you can expect consistent performance across lots, eliminating the variability that often complicates experiments using traditional hybridoma-derived reagents. The human IgG1 isotype and affinity-chromatography purification ensure high purity suitable for sensitive detection assays.
Functional ELISA validation demonstrates robust binding characteristics, with the antibody recognizing immobilized human TSLP protein at an EC50 of approximately 5.5–6.2 ng/mL. Notably, testing against a TSLP variant carrying R127A and R130A mutations showed retained binding with an EC50 of 52.6–58.7 ng/mL, providing useful information about epitope characteristics for researchers working with modified TSLP constructs. The antibody exhibits cross-species reactivity with both human and mouse TSLP, supporting comparative studies across these commonly used model systems.
Optimized for ELISA applications at dilutions ranging from 1:5,000 to 1:50,000, this antibody serves immunology researchers investigating allergic disease mechanisms, epithelial-immune crosstalk, and cytokine-driven inflammatory pathways.
Email: support@cusabio.com
Distributors Worldwide